TABIN JULIUS Form SC 13D December 26, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

(Name of Issuer)

Common Stock, Par Value \$.01

(Title of Class of Securities)

042698308

(CUSIP Number)

Mr. Julius Tabin
Fitch, Even, Tabin & Flannery
120 South LaSalle Street, Suite 1600
Chicago, Illinois 60603
(312) 372-7842

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

November 14, 2002

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].

Check the following box if a fee is being paid with the statement [_]. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

NOTE: Six copies of this statement, including one original and all exhibits, should be filed with the Commission. See Rule 13-d1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page

shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP	NO. 04269830)8 	SCHEDULE 13D	PAGE 2 OF	3 PAGES					
1.	Name of Reporting Persons I.R.S. Identification Nos. of above persons (entities only). Julius Tabin									
2.	Check the A (a) [_] (b) [_]		if a Member of a G	Group (See Instruction	s)					
3.	SEC Use Onl									
4.	Source of Funds (See Instructions) PF									
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) [_]									
6.	Citizenshir	or Place of O	rganization							
			U.S.							
		7. Sole Vot 138,82	ing Power 4 Shares Common Sto	ock, \$.01 Par Value						
Number of Shares Beneficially by Owned by Each Reporting Person With		8. Shared V	Shared Voting Power							
		9. Sole Dispositive Power 138,824 Shares Common Stock, \$.01 Par Value								
		10. Shared D	ispositive Power							
11.			ally Owned by Each Stock, \$.01 Par Val	-						
12.	Check Box	f the Aggregat	e Amount in Row (11	.) Excludes Certain Sh	ares* [_]					
13.	Percent of	Class Represen	ted by Amount in Ro	ow (11)						

5.1%

14. Type of Reporting Person (See Instructions)

ΤN

*See Instructions before filling out.

CUSIP NO. 042698308

SCHEDULE 13D

PAGE 3 OF 3 PAGES

Item 1. Security and Issuer

This statement relates to the \$.01 Par Value Common Stock ("Common Stock") of Arrhythmia Research Technology, Inc. ("ART"), the principal executive offices of which are located at 25 Sawyer Passway, Fitchburg, Massachusetts 01420

Item 2. Identity and Background

- (a) Julius Tabin
- (b) Mr. Tabin's business address is Fitch, Even, Tabin & Flannery, 120 South LaSalle Street, Suite 1600, Chicago, IL 60603
- (c) Mr. Tabin's principal occupation is as a partner in the previous listed law firm.
- (d) Mr. Tabin has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five
- (e) Mr. Tabin has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of any such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.
- (f) Mr. Tabin is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration

The Common Stock of ART acquired by Mr. Tabin has been purchased for an aggregate cash consideration of \$158,236.14, utilizing personal funds.

Item 4. Purpose of Transaction

Mr. Tabin has purchased the Common Stock of ART for investment purposes.

Item 5. Interest in Securities of the Issuer

The aggregate number of shares of Common Stock of ART beneficially owned by Mr. Tabin and the percentage which those shares are of the outstanding Common Stock of ART are as follows:

Julius Tabin 138,824 shares 5.1%

- (b) Mr. Tabin has the sole power to vote and the sole power to dispose or direct the disposition of all of the shares of Common Stock listed in subpart (a) of this Item.
- (c) The following transactions in the Common Stock of ART were completed to attain 5% ownership:

Amount of Price / Where and

Amount of Price / Where _____

Date	Securities	Share	How Effected	Date	Securities	Share	Eff
11/06/87	15,000*		Initial	10/08/98	3 , 200	\$1.0625	Open
03/08/88		3:2	Rev Stk Split	10/13/98	8,000	\$1.0625	Open
07/21/88	4,809*			10/15/98	200	\$1.0625	Open
05/23/89	566*			10/23/98	1,700	\$1.0625	Open
09/06/89		2:1	Rev Stk Split	10/27/98	6,700	\$1.0625	Open
08/06/90		2:1	Rev Stk Split	10/28/98	200	\$1.0625	
03/01/95	8,103	\$1.88	Open Market	04/23/99	8,333	\$1.0000	Comp.fo
08/27/97	20,400	\$1.88	Open Market	05/10/00	4,103	\$1.5000	Comp.fo
09/02/97	6,500	\$1.88	Open Market	01/10/02	8,000	\$1.0625	Exero
09/03/97	3,100	\$1.88	Open Market				

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

* Reverse split adjusted quantity

Mr. Tabin does not have any contracts, arrangements, understandings, or relationships (legal or otherwise) with any persons with respect to any securities of ART, including but not limited to transfer or voting of any securities of ART, finders fees; joint ventures; loan or option arrangements; puts or calls; guarantees of profits; divisions of profits or losses; or the giving or withholding of proxies.

After reasonable inquiry and to the best knowledge and belief of each, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: November 22, 2002 /s/ Julius Tabin
----Julius Tabin